Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT(1A), and adrenergic α1 receptors

Journal of Medicinal Chemistry

Volumn 41, Issue 12, 1998, Pages 1997-2009

  Reitz, Allen B ^a   Baxter, Ellen W ^a   Codd, Ellen E ^a   Davis, Coralie B ^a   Jordan, Alfonzo D ^a   Maryanoff, Bruce E ^a   Maryanoff, Cynthia A ^a   McDonnell, Mark E ^a   Powell, Eugene T ^a   Renzi, Michael J ^a   Schott, Mary R ^a   Scott, Malcolm K ^a   Shank, Richard P ^a   Vaught, Jeffry L ^a,b  

^a R W JOHNSON PHARMACEUTICAL RES I   (United States)

^b Cephalon Inc

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 [[4 (2 ISOPROPOXYPHENYL) 1 PIPERIDINYL]METHYL]BENZOYL]PIPERIDINE; ALPHA 1 ADRENERGIC RECEPTOR; BENZAMIDE DERIVATIVE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; MAZAPERTINE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; RISPERIDONE; RWJ 25730; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ADRENERGIC AGENTS; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CATALEPSY; CEREBRAL CORTEX; CONDITIONING (PSYCHOLOGY); CORPUS STRIATUM; DOPAMINE AGENTS; HUMANS; MALE; PIPERAZINES; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGENTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15144346396     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970164z     Document Type: Article

References (74)

1. (a) Frankenburg, F. R.; Hegarty, J. D. Cost Considerations in the Treatment of Schizophrenia. CNS Drugs 1996, 5, 75-82.
2. (b) Lindstrom, E. The Hidden Cost of Schizophrenia. J. Drug Dev. Clin. Pract. 1996, 7, 281-288.
3. (c) Tamminga, C. A., Schulz, S. C., Eds. Advances in Neuropsychiatry and Psychopharmacology, Volume I: Schizophrenia Research; Raven Press: New York, 1991.
4. (d) Meltzer, H. Y. Psychopharmacology: The Third Generation of Progress; Raven Press: New York, 1987.
5. (e) Reynolds, G. P. Developments in the Drug Treatment of Schizophrenia. Trends Pharmacol. Sci. 1992, 13, 116-121.
6. (f) Trickle-bank, M. D.; Bristow, L. J.; Hutson, P. H. Alternative Approaches to the Discovery of Novel Antipsychotic Agents. Prog. Drug Res. 1992, 38, 299-336.
7. (g) Owens, D. G. C. Adverse Effects of Antipsychotic Agents. Drugs 1996, 51, 895-930.
8. Murray, R. M., Turner, T. H., Eds. Lectures on the History of Psychiatry; Alden Press: London, 1990.
9. (a) Swazey, J. P. Chlorpromazine in Therapy: A Study of Therapeutic Intervention; The MIT Press: Cambridge, MA, 1974.
10. (b) Courvoisier, S.; Fournel, J.; Ducrot, R.; Kolsky, M.; Koetschet, P. Proprietes Pharmadynamiques Du Chlorhydrate De Chloro- 3-(dimethylamino-3′-propyl)-10 Phenothiazine (4.560 R.P.). Arch. Int. Pharmacodyn. Ther. 1953, 92, 305-361.
11. Frances, A. J.; Weiden, P. Promoting Compliance With Outpatient Drug Treatment. Hosp. Community Psychiatry 1987, 38, 1158-1160.
12. 4. Neuropsychopharmacology 1992, 7, 261-284.
13. (b) Sibley, D. R.; Monsma, F. J., Jr. Molecular Biology of Dopamine Receptors. Trends Pharmacol. Sci. 1992, 7, 61-69.
14. 4 Receptors Elevated in Schizophrenia. Nature 1993, 365, 441-445.
15. 3) as a Novel Target for Antipsychotics. Biochem. Pharmacol. 1992, 43, 659-666.
16. (e) Civelli, O.; Bunzow, J. R.; Grandy, D. K.; Zhou, Q.-Y.; Van Tol, H. H. M. Molecular Biology of the Dopamine Receptors. Eur. J. Pharmacol. - Mol. Pharmacol Sect. 1991, 207, 277-286.
17. (f) Thurkaff, A.; Yuan, J.; Chen, X.; Wasley, J. W. F.; Paneitz, G.; Meade, R.; Woodruff, K. H.; Huston, K.; Ross, P. C. 3-Aminomethylbiphenyls. A New Class of Dopamine Receptor Ligands. Med. Chem. Res. 1996, 6, 69-80 and references therein.
18. (a) McDonnell, M. E.; Reitz, A. B. Recent Advances in Antipsychotic Research. Expert Opin. Ther. Pat. 1994, 4, 1221-1231.
19. (b) Howard, H. R.; Seeger, T. F. Novel Antipsychotics. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: San Diego, 1993; Vol. 28, Chapter 5, pp 39-47.
20. (c) Cipollina, J. A. New Antipsychotic Agents: A Patent Overview - 1991. Curr. Opin. Ther. Pat. 1992, 2, 485.
21. (d) Horn, A. S. Dopamine Receptors. In Comprehensive Medicinal Chemistry; Emmett, J. C., Ed.; Pergamon Press: New York, 1990; Vol. 3, p 229.
22. (e) Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine for the Treatment-Resistant Schizophrenic. Arch. Gen. Psychiatry 1988, 45, 789-796.
23. (f) Honigfeld, G.; Patin, J.; Singer, J. Adv. Ther. 1984, 7, 77-97.
24. (g) Kaiser, C.; Setler, P. E. Antipsychotic Agents. In Burger's Medicinal Chemistry, Wolff, M. E., Ed.; John Wiley & Sons: New York, 1980; Part III, p 859.
25. For reviews on the multiplicity of serotomin subtypes, see: (a) Saudou, F.; Hen, R. 5-HT Receptor Subtypes: Molecular and Functional Diversity. Med. Chem. Res. 1994, 4, 16-84. (b) Gothert, M. 5-Hydroxytryptamine Receptors. Arzneimforsch 1992, 42, 238-249.
26. For reviews on the multiplicity of serotomin subtypes, see: (a) Saudou, F.; Hen, R. 5-HT Receptor Subtypes: Molecular and Functional Diversity. Med. Chem. Res. 1994, 4, 16-84. (b) Gothert, M. 5-Hydroxytryptamine Receptors. Arzneimforsch 1992, 42, 238-249.
27. (a) Meltzer, H. Y.; Nash, J. F. Effects of Antipsychotic Drugs on Serotonin Receptors. Pharmacol. Rev. 1991, 43, 587-604.
28. (b) Abi-Dargham, An.; Laruelle, M.; Charney, D.; Krystal, J. Serotonin and Schizophrenia: A Review. Drugs Today 1996, 32, 171-185.
29. 2 Antagonistic Properties. J. Pharmacol. Exp. Ther. 1988, 244, 685-693.
30. (b) Leysen, J. E.; Gommeren, W.; Eens, A.; De Chaffoy De Courcelles, D.; Stoof, J. C.; Janssen, P. A. J. Biochemical Profile of Risperidone, A New Antipsychotic. J. Pharmacol. Exp. Ther. 1988, 247, 661-670.
31. (c) Risperidone. Drugs Future 1988, 73, 1052-1055.
32. For an early comparison of the pharmacological activity of dopamine antagonists, see: Niemegeers, C. J. E.; Janssen, P. A. J. A Systematic Study of the Pharmacological Activities of Dopamine Antagonists. Life Sci. 1979, 24, 2201-2216.
33. Martin, G. E.; Elgin, R. J., Jr.; Mathiasen, J. R.; Davis, C. B.; Kesslick, J. M.; Baldy, W. J.; Shank, R. P.; DiStefano, D. L.; Fedde, C. L.; Scott, M. K. Activity of Aromatic Substituted Phenylpiperazines Lacking Affinity for Dopamine Binding Sites in a Preclinical Test of Antipsychotic Efficacy. J. Med. Chem. 1989, 32, 1052-1056.
34. Scott, M. K.; Martin, G. E.; DiStefano, D. L.; Fedde, C. L.; Kukla, M. J.; Barrett, D. L.; Baldy, W. J.; Elgin, R. J., Jr.; Kesslick, J. M.; Mathiasen, J. R.; Shank, R. P.; Vaught, J. L. Pyrrole Mannich Bases as Potential Antipsychotic Agents. J. Med. Chem. 1992, 35, 552-558.
35. 1A Affinity and Minimal Extrapyramidal Side-Effect Liability. In Advances in Medicinal Chemistry; Maryanoff, B. E., Maryanoff, C. A., Eds.; JAI Press: Greenwich, CT, 1995; Vol. 3, pp 1-56.
36. (a) Scott, M. K.; Baxter, E. W.; Bennett, D. J.; Boyd, R. E.; Blum, P. S.; Codd, E. E.; Kukla, M. J.; Malloy, E.; Maryanoff, B. E.; Maryanoff, C. A.; Ortegon, M. E.; Rasmussen, C. R.; Reitz, A. B.; Renzi, M. J.; Schwender, C. F.; Shank, R. P.; Sherrill, R. G.; Vaught, J. L.; Villani, F. J.; Yim, N. Piperazinylalkyl Heterocycles as Potential Antipsychotic Agents. J. Med. Chem. 1995, 38, 4198-4210.
37. (b) Reitz, A. B.; Baxter, E. W.; Bennett, D. J.; Codd, E. E.; Jordan, A. D.; Malloy, E. A.; Maryanoff, B. E.; McDonnell, M. E.; Ortegon, M. E.; Renzi, M. J.; Scott, M. K.; Shank, R. J.; Sherrill, R. G.; Vaught, J. L.; Wustrow, D. J. N-Aryl-N′-Benzylpiperazines as Potential Antipsychotic Agents. J. Med. Chem. 1995, 38, 4211-4222.
38. 1A/α1A-Adrenergic Affinity and a Low Potential for Extrapyramidal Effects. J. Med. Chem. 1994, 37, 1060-1062.
39. 1A Receptor Affinities. Chem. Pharm. Bull. 1991, 39, 3370-3372.
40. 1A Receptor Affinities. Chem. Pharm. Bull. 1991, 39, 3370-3372.
41. 1A Receptor Affinities. Chem. Pharm. Bull. 1991, 39, 3370-3372.
42. 1A Receptor Affinities. Chem. Pharm. Bull. 1991, 39, 3370-3372.
43. 1A Receptor Affinities. Chem. Pharm. Bull. 1991, 39, 3370-3372.
44. 1A Receptor Affinities. Chem. Pharm. Bull. 1991, 39, 3370-3372.
45. 1A Receptor Affinities. Chem. Pharm. Bull. 1991, 39, 3370-3372.
46. 1A Receptor Affinities. Chem. Pharm. Bull. 1991, 39, 3370-3372.
47. Clineschmidt, B. V.; McKendry, M. A.; Papp, N. L.; Pflueger, A. B.; Stone, C. A.; Totaro, J. A.; Williams, M. Stereospecific Antidopaminergic and Anticholinergic Actions of the Enantiomers of (±)-1-Cyclopropylmethyl-4-(3-trifluoromethylthio-5H- dibenzo[a,d]cyclohepten-5-ylidene)piperidine (CTC), a Derivative of Cyproheptadine. J. Pharmacol. Exp. Ther. 1979, 208, 460- 476.
48. Reitz, A. B.; McDonnell, M. E.; Baxter, E. W.; Codd, E. E.; Wu, W.-N. The Synthesis and Evaluation of the Major Metabolites of Mazapertine. Bioorg. Med. Chem. Lett. 1997, 7, 1927-1930.
49. 2 Binding Characteristics of Some Quipazine Derivatives J. Med. Chem. 1996, 29, 2375- 2380.
50. (b) van Wijngaarden, I.; Kruse, C. G.; van der Heyden; Tulp, M. Th. M. 2-Phenylpyrroles as Conformationally Restricted Benzamide Analogues. A New Class of Potential Antipsychotics. J. Med. Chem. 1988, 31, 1934-1940.
51. (c) Olivier, B.; Mos, J.; Hartog, J.; Rasmussen, D. Serenics. Drug News Perspect. 1990, 3, 261-271.
52. 1 Receptor Sites in the Rat Brain: an Autoradiographic Study. Eur. J. Pharmacol. 1990, 177, 55-66.
53. 1A Receptor Ligands: Synthesis and Structure-Affinity Relationships. J. Med. Chem. 1995, 38, 4303-4308.
54. (a) Yevich, J. P. Drug Development: From Discovery to Marketing. In A Textbook of Drug Design and Development; Krogsgaard- Larsen, P., Bundgaard, H., Eds.; Harwood Academic Publishers: Philadelphia, 1991; pp 606-630.
55. 1A Receptor-Related Anxiolytics. Trends Pharmacol. Sci. 1987, 8, 432-437.
56. 3H]Spiperone Binding of 3,5-Disubstituted N-[(1- Ethyl-2-pyrrolidinyl)methyl]-6-methoxysalicylamides. J. Med. Chem. 1986, 29, 61-69.
57. (b) de Paulis, T.; Kumar, Y.; Johansson, L.; Ramsby, S.; Florvall, L.; Hall, H.; Angeby-Moller, K.; Ogren, S.-O. Potential Neuroleptic Agents. 3. Chemistry and Antidopaminergic Properties of Substituted 6-Methoxysalicylamides. J. Med. Chem. 1985, 28, 1263-1269.
58. Schoenberg, A.; Heck, R. F. Palladium-Catalyzed Amidation of Aryl, Heterocyclic, and Vinylic Halides. J. Org. Chem. 1974, 37, 3327-3331.
59. Levy, L. A. Synthesis of W-Methoxybenzisothiazole Derivatives. J. Heterocycl. Chem. 1971, 8, 873-874.
60. Martin, G. E.; Elgin, R. J., Jr.; Kesslick, J. M.; Baldy, W. J.; Mathiasen, J. R.; Shank, R. P.; Scott, M. K. Block of Conditioned Avoidance Responding in the Rat by Substituted Phenylpiperazines. Eur. J. Pharmacol. 1988, 156, 223-229.
61. (a) Neal-Beliveau, B. S.; Joyce, J. N.; Lucki, I. Serotonergic Involvement in Haloperidol-Induced Catalepsy. J. Pharmacol. Exp. Ther. 1993, 265, 207-217.
62. (b) Wadenberg, M. L.; Ahlenius, S. Antipsychotic-Like Profile of Combined Treatment With Raclopride and 8-OH-DPAT in the Rat: Enhancement of Antipsychotic-Like Effects Without Catalepsy. J. Neural Trans. 1991, 83, 43-53.
63. (c) Hicks, P. B. The Effect of Serotonergic Agents on Haloperidol-Induced Catalepsy. Life Sci. 1990, 47, 1609-1615.
64. (d) McMillen, B. A.; Scott, S. M.; Davanzo, E. A. Reversal of Neuroleptic-Induced Catalepsy by Novel Aryl- Piperazine Anxiolytic Drugs. J. Pharm. Pharmacol. 1988, 40, 885-887.
65. (a) Goff, D. C.; Midha, K. K.; Brotman, A. W.; McCormick, S.; Waites, M.; Amico, E. T. An Open Trial of Buspirone Added to Neuroleptics in Schizophrenic-Patients. J. Clin. Psychopharmacol 1991, 11, 193-197.
66. (b) Moss, L. E.; Neppe, V. M.; Crevets, W. C. Buspirone in the Treatment of Tardive Dyskinesia. J. Clin. Psychopharmacol. 1993, 13, 204-209.
67. (c) Neal Beliveau, B. S.; Joyce, J. N.; Lucki, I. Serotonergic Involvement in Haloperidol- Induced Catalepsy. J. Pharmacol. Exp. Ther. 1993, 265, 207- 217.
68. (d) D'Mello, D. A.; McNeil, J. A.; Harris, W. Buspirone Suppression of Neuroleptic-Induced Akathesia: Multiple Case Reports. J. Clin. Psychopharmacol. 1989, 9, 151-152.
69. 1A Receptors. J. Med. Chem. 1993, 36, 1509- 1510.
70. 1-Noradrenergic Receptors Demonstrated by In vivo Voltammetry. Brain Res. 1988, 460, 398-401.
71. (a) Hansch, C.; Bjorkroth, J. P.; Leo, A. Hydrophobicity and Central Nervous System Agents: On the Principle of Minimal Hydrophobicity in Drug Design. J. Pharm. Sci. 1987, 76, 663- 687.
72. (b) Hansch, C.; Leo, A.; Hoekman, D. Exploring QSAR Hydrophobic, Electronic, and Steric Constants; ACS Professional Reference Book; American Chemical Society: Washington, DC, 1995.
73. For computational analysis of arylpiperazine conformation, see: Dijkstra, G. D. H. Conformational Analysis of 1-Arylpiperazines and 4-Arylpiperidines. Recl. Trav. Chim. Pays-Bas 1993, 112, 151-160.
74. i) and the Concentration of Inhibitor Which Causes 50% Inhibition of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.